CHO-H01 / Cho Pharma - LARVOL DELTA

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=37 | Active, not recruiting | Sponsor: Cho Pharma Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Study to Assess Safety and Efficacy of CHO-H01 As a Single Agent/Combined with Lenalidomide in Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: Cho Pharma Inc. | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: Cho Pharma Inc. | N=11 ➔ 37 | Trial completion date: Feb 2024 ➔ Jun 2026 | Trial primary completion date: Nov 2023 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=11 | Recruiting | Sponsor: Cho Pharma Inc.

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20